Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac for the Northern Hemisphere Season 2013/2014. An Open-Label, Baseline- Controlled Study in Two Age Groups: Adult Subjects ≥ 18 and ≤ 60 Years and Elderly Subjects ≥ 61 Years of Age.

Trial Profile

Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac for the Northern Hemisphere Season 2013/2014. An Open-Label, Baseline- Controlled Study in Two Age Groups: Adult Subjects ≥ 18 and ≤ 60 Years and Elderly Subjects ≥ 61 Years of Age.

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Aug 2014

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Abbott Biologicals BV
  • Most Recent Events

    • 30 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top